lesinurad (Zurampic)
Jump to navigation
Jump to search
Indications
- treatment of gout
- for use in conjunction with xanthine oxidase inhibitor
- for patients who have not achieved serum uric acid targets with xanthine oxidase inhibitor (allopurinol or febuxostat) alone[1]
Contraindications
- severe renal impairment, ESRD
Dosage
Pharmacokinetics
- absorption 100%
- 98% protein bound, mainly to albumin
- 1/2 life 5 hours
- does not accumulate with multiple doses
- plasma levels not significantly altered by renal insufficiency or hepatic insufficiency
Adverse effects
- headache, influenza, increased blood creatinine, and gastroesophageal reflux disease[1]
* boxed warning: risk for acute renal failure, higher when used alone[1]
Mechanism of action
- inhibits the function of URAT1 involved in reabsorption of uric acid in the renal tubules
More general terms
Component of
References
- ↑ Jump up to: 1.0 1.1 1.2 1.3 FDA News Release. December 22, 2015 FDA approves Zurampic to treat high blood uric acid levels associated with gout. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm478791.htm
- ↑ lesinurad (Zurampic) prescribing information http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf